Rytelo™

Understanding Rytelo™ 

Rytelo™ (imetelstat) is a first-in-class telomerase inhibitor approved for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. This therapy is specifically designed for individuals requiring four or more red blood cell (RBC) units over eight weeks and who have not responded to, have lost response to, or are ineligible for erythropoiesis-stimulating agents (ESAs).

How Rytelo™ Works:

• Telomerase Inhibition: Imetelstat targets and inhibits telomerase, an enzyme that enables the uncontrolled proliferation of malignant cells. By blocking telomerase activity, Rytelo™ leads to the shortening of telomeres, resulting in reduced replication of malignant cells and potential disease modification.

• Reduction in Transfusion Dependency: Clinical trials have demonstrated that Rytelo™ can significantly decrease the need for RBC transfusions in patients with transfusion-dependent anemia due to MDS.

• Administration: Rytelo™ is administered via intravenous infusion over a period of two hours. The treatment schedule typically involves infusions every four weeks, with the exact regimen tailored to the patient’s response and clinical condition.

FDA Approval:

• Rytelo™ received approval from the U.S. Food and Drug Administration (FDA) on June 6, 2024, for the treatment of adult patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia.

For more information, please visit the Rytelo™ patient website and consult your healthcare provider to determine if Rytelo™ is the appropriate treatment option for you.